Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pfizer (NY:PFE)

24.48 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Jul 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
Donald Trump's Drug-Pricing Deals Are Reshaping Big Pharma -- Here's What That Means for Pfizer, AbbVie, and Bristol Myers Squibb ↗
Drug pricing matters, but pipelines matter even more. 
Via The Motley Fool
Topics Government Intellectual Property
Stay informed about the most active stocks in the S&P500 index on Monday's session. ↗
Via Chartmill
News headline image
The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions ↗
Wainua missed its Phase 3 endpoint, hitting Ionis Pharmaceuticals hard while AstraZeneca absorbed the blow easily, boosting rivals BridgeBio, Pfizer and Alnylam Pharmaceuticals. 
Via MarketBeat
News headline image
2 Value Stocks Worth Your Attention and 1 Facing Headwinds
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The ... 
Via StockStory
News headline image
3 High-Yield Dividend Stocks Paying 5% or More That Are Worth Buying Now ↗
These high-yield stocks have long track records of dividend consistency and growth. 
Via The Motley Fool
News headline image
Should You Buy Eli Lilly Stock? Here's My Honest Take. ↗
There are good reasons to invest in Lilly and to hold off. 
Via The Motley Fool
News headline image
Is Pfizer on Track to Launch Its Next Lipitor -- This Time in the Weight-Loss Market? ↗
So far, Pfizer has been an also-ran in the GLP-1 race, but that could change if its long-acting weight-loss medication takes off. 
Via The Motley Fool
News headline image
Pfizer, Astellas Expand PADCEV-Keytruda Label With FDA Nod In Bladder Cancer ↗
FDA approves Pfizer and Astellas' PADCEV plus Keytruda for muscle-invasive bladder cancer, backed by Phase 3 survival data. 
Via Benzinga
News headline image
U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
From Pfizer Inc.
Via Business Wire
News headline image
2 Value Stocks with Promising Prospects and 1 That Underwhelm
Value investing has produced some of the world’s most famous investing billionaires, including Warren Buffett, David Einhorn, and Seth Klarman, who built the... 
Via StockStory
News headline image
1 Healthcare Stock with Solid Fundamentals and 2 We Brush Off
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have be... 
Via StockStory
News headline image
Why AstraZeneca Crashed 8%, Leading Three Rivals, Including Pfizer, To Jump ↗
AstraZeneca stock crashed Thursday after its Ionis-partnered treatment for a rare heart disease failed in Phase 3 testing. 
Via Investor's Business Daily
News headline image
2 Dirt Cheap Dividend Stocks to Buy With $1,000 Right Now ↗
They may not remain cheap for too much longer. 
Via The Motley Fool
Topics Intellectual Property
These S&P500 stocks are the most active in today's session ↗
Via Chartmill
News headline image
Opinion: Pfizer's Dividend Is Riskier Than You Might Think ↗
A 7% dividend yield will grab your attention, but be sure to read the fine print. 
Via The Motley Fool
Topics Earnings Intellectual Property
News headline image
Hospira Brand Bacteriostatic Water: Uses, Safety, and Clinical Guidelines ↗
Hospira brand bacteriostatic water is a sterile, non-pyrogenic preparation of water for injection that contains 0.9 
Via Talk Markets
News headline image
Pfizer's Growth Story Faces a Wait as Pipeline and Leadership Doubts Mount ↗
Pfizer was downgraded to Hold as analysts cited delayed pipeline catalysts, management changes and reduced near-term re-rating potential. 
Via Benzinga
Explore the S&P500 index on Monday and find out which stocks are the most active in today's session. ↗
Via Chartmill
News headline image
Meet the 4 S&P 500 Dividend Stocks That Yield at Least 6%. Here's My Strongest Buy of the Bunch in July. ↗
One stands above the others. 
Via The Motley Fool
Topics Stocks
News headline image
Pfizer's CEO Says His Company Has a "Very Big Balance Sheet" to Do Deals. Here's the Perfect Next Acquisition Target for the Pharma Giant ↗
Could this be the secret to Pfizer's rebound strategy? 
Via The Motley Fool
News headline image
OS Therapies Appoints Dr. Craig Eagle to Board of Directors
Company secures $10 million line of credit supported by OS Therapies UK tax creditsNew York, New York and Rockville, Maryland--(Newsfile... 
Via Newsfile
News headline image
Wall Street Thinks This Biotech Stock Can Soar 45%. Here's Why Analysts Are Right. ↗
Analysts have given Alnylam Pharmaceuticals an average price target of $436. 
Via The Motley Fool
News headline image
2 of Wall Street’s Favorite Stocks Worth Your Attention and 1 We Turn Down
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptic... 
Via StockStory
News headline image
Pfizer vs Verizon Communications: Which High-Yielding Dividend Stock Is the Better Buy? ↗
These stocks offer high yields, are big names in their respective sectors, and have strong fundamentals. 
Via The Motley Fool
News headline image
Branded Pharmaceuticals Stocks Q1 Teardown: Zoetis (NYSE:ZTS) Vs The Rest
Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at Zoetis (NYSE:ZTS) and its pee... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
The Fine Print Most Canadians Miss When Holding U.S. Stocks in a TFSA ↗
Maximize your investment opportunities in US stocks with a TFSA while being aware of the tax implications of dividends. 
Via The Motley Fool
Topics Artificial Intelligence ETFs Retirement
Looking for the most active stocks in the S&P500 index on Tuesday? ↗
Via Chartmill
News headline image
Why Pfizer Could Prove to Be an Underrated GLP-1 Stock ↗
It could prove to be a case of better later than never for the healthcare giant. 
Via The Motley Fool
Topics Earnings
News headline image
Big Pharma Has a Case of Merger Mania ↗
Pharmaceutical companies are on an M&A spree that could break records this year as they look for novel drug and clinical-stage candidates to bolster the development pipeline. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Nike Just Hit an 11-Year Low. Will Its Turnaround Finally Start on Wednesday? ↗
Nike is set to report earnings on June 30. Here's what to expect. 
Via The Motley Fool
Topics World Trade
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.